GlobalData, the industry analysis specialist, has released its new report, “Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global rheumatoid arthritis therapeutics market. The report identifies the key trends shaping and driving the global rheumatoid arthritis therapeutics market.
ReportsnReports – Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018
1. Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to
2018
ReportsnReports.com adds GlobalData Market Research Report “Rheumatoid Arthritis
Therapeutics – Pipeline Assessment and Market Forecasts to 2018 ’’ to its store.
GlobalData, the industry analysis specialist, has released its new report, “Rheumatoid
Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is
an essential source of information and analysis on the global rheumatoid arthritis
therapeutics market. The report identifies the key trends shaping and driving the
global rheumatoid arthritis therapeutics market.
The report also provides insights on the prevalent competitive landscape and the emerging
players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the
global rheumatoid arthritis therapeutics sector. This report is built using data and
information sourced from proprietary databases, primary and secondary research and in-
house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the rheumatoid
arthritis therapeutics market. Its scope includes -
Annualized revenue data from seven key markets (the US, France, Germany, Italy,
Spain, the UK and Japan) in the rheumatoid arthritis therapeutics market from 2005 to
2010, and forecasts for eight years to 2018.
Pipeline analysis data, providing analysis split across the different phases, mechanisms
of action being developed and emerging trends in the pipeline. Pipeline candidates fall
under a variety of major therapeutic classes such as p38 kinase inhibitors, Janus Kinase
Inhibitors (JAK), tyrosine kinase inhibitors, dihydrofolate reductase inhibitors,
cyclooxygenase (COX) inhibitors, Dihydroorotate dehydrogenase (DHODH) inhibitors,
interleukin inhibitors, tumor necrosis factor (TNF) inhibitors, chemotaxis inhibitors,
Vascular Adhesion Protein-1 (VAP 1) inhibitors, granulocyte macrophage colony
stimulating factor (GM-CSF) inhibitors, Toll-like receptors (TLRs) and anti-CD 20
monoclonal antibodies.
Analysis of the current and future competition in the global rheumatoid arthritis
therapeutics market. The key market players covered are AstraZeneca PLC, Eli Lilly and
Company Eisai Co., Ltd GlaxoSmithKline plc, Pfizer Inc, Sanofi, Merck & Co., Inc.,
Novartis AG and Regeneron Pharmaceuticals, Inc.
Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization,
unmet needs and the implications for the rheumatoid arthritis therapeutics market.
Analysis of key recent licensing and partnership agreements in the rheumatoid arthritis
therapeutics market.
2. Reasons to buy
The report will enhance your decision-making capability. It will allow you to -
Develop and design your in-licensing and out-licensing strategies through a review of
pipeline products and technologies and by identifying the companies with the most
robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global
rheumatoid arthritis therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global rheumatoid arthritis
therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and
segments that present the best opportunities for consolidations, investments and
strategic partnerships.
What’s the next big thing in the global rheumatoid arthritis therapeutics market
landscape? – Identify, understand and capitalize.
Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Rheumatoid Arthritis Therapeutics Market – Introduction 7
2.1 Disease Overview 7
2.1.1 Classification and Diagnosis Criteria for Rheumatoid Arthritis 8
2.2 Epidemiology 8
2.3 Etiology 9
2.4 Sign and Symptoms 9
2.5 Diagnosis 10
2.5.1 Blood Tests 10
2.5.2 X-rays Testing 10
2.6 Pathophysiology 11
2.7 Treatment and Management Pattern 12
2.8 GlobalData Pipeline Report Guidance 13
3 Rheumatoid Arthritis Therapeutics – Market Characterization 14
3.1 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Global 14
3.2 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Global 16
3.3 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – The US 18
3.4 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – The US 19
3.5 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – France 20
3.6 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – France 21
3.7 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Germany 22
3.8 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Germany 23
3.9 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Italy 24
3.10 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Italy 25